Domov › Urotelialni (prehodnocelični) karcinom › New York › New York City
Klinične študije za Urotelialni (prehodnocelični) karcinom v New York City, NY
22 študij za Urotelialni (prehodnocelični) karcinom išče udeležence na lokacijah v New York City in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Vključevanje udeležencevFaza 1
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Vključevanje udeležencevFaza 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Vključevanje udeležencevOpazovalna študija
- NYU Grossman School of Medicine, New York
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Vključevanje udeležencevFaza 1/2
- Memorial Sloan Kettering Cancer Center ( Site 1031), New York
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Vključevanje udeležencevFaza 1/2
- Icahn School of Medicine at Mount Sinai, New York
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Columbia University Irving Medical Center, New York
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Vključevanje udeležencevFaza 3
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medical College, New York
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
Vključevanje udeležencevFaza 1
- Mount Sinai Hospital, New York
- NYP/Weill Cornell Medical Center, New York
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Vključevanje udeležencevFaza 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Vključevanje udeležencevFaza 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Tisch Cancer Institute (TCI), Icahn School of Medicine, New York
- Columbia University, New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Vključevanje udeležencevFaza 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Vključevanje udeležencevFaza 1
- New York Cancer & Blood Specialists, New York
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Vključevanje udeležencevFaza 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Vključevanje udeležencevFaza 2
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Icahn School of Medicine at Mount Sinai, New York
- Evelyn H. Lauder Breast and Imaging Centre (BAIC), New York
- in še 2
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Vključevanje udeležencevFaza 3
- Research Site, New York
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Vključevanje udeležencevFaza 2
- Memorial Sloan Kettering Cancer Center, New York
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Vključevanje udeležencev
- Integrated Medical Professionals, New York
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Vključevanje udeležencevFaza 1
- MSK, New York
A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma
Vključevanje udeležencevOpazovalna študija
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
Vključevanje udeležencevFaza 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Vključevanje udeležencevOpazovalna študija
- Massive Bio SYNERGY-AI site, New York
Študije za Urotelialni (prehodnocelični) karcinom v drugih mestih
- Nashville, TN23 študij
- Houston, TX19 študij
- Dallas, TX18 študij
- Edison, NJ18 študij
- Los Angeles, CA17 študij
- Queens, NY15 študij
- Chicago, IL14 študij
- Arlington, VA12 študij
- Boston, MA11 študij
- San Antonio, TX11 študij
- Austin, TX10 študij
- Orange, CA10 študij
Druge študije v New York City
- Rak dojke136 študij
- Nemalicelični pljučni rak121 študij
- Rak (vse vrste)109 študij
- Rak prostate103 študij
- Metastatski rak93 študij
- Kolorektalni rak78 študij
- Rak jajčnikov69 študij
- Rak pljuč60 študij
- Množni mielom60 študij
- Rak trebušne slinavke60 študij
- Rak endometrija52 študij
- Akutna mieločna levkemija51 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.